Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

Group 1 - Zenas BioPharma, Inc. (NASDAQ: ZBIO) is a biotech company based in Waltham, Massachusetts, which completed its IPO in September last year, raising $225 million by issuing approximately 13.24 million shares priced at $17 each [1] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts to watch for, buy and sell ratings, product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies in the biotech, healthcare, and pharma sectors [1]